Omalizumab for chronic urticaria in Latin America.

Item

http://www.wikidata.org/entity/Q37431777

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Omalizumab for chronic urticaria in Latin America.

@en

Omalizumab for chronic urticaria in Latin America.

@nl

type

Item

label

Omalizumab for chronic urticaria in Latin America.

@en

Omalizumab for chronic urticaria in Latin America.

@nl

prefLabel

Omalizumab for chronic urticaria in Latin America.

@en

Omalizumab for chronic urticaria in Latin America.

@nl

P1476

Omalizumab for chronic urticaria in Latin America

@en

P2093

Annia Cherrez

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Calderon

http://www.w3.org/2001/XMLSchema#string

Paola Wilches

http://www.w3.org/2001/XMLSchema#string

Paul Wilches

http://www.w3.org/2001/XMLSchema#string

P2860

Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.

Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.

Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria.

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

P2888

s40413-016-0127-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40413-016-0127-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ivan Cherrez Ojeda

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033492974

http://www.w3.org/2001/XMLSchema#string

P698

27942350

http://www.w3.org/2001/XMLSchema#string

P932

5120491

http://www.w3.org/2001/XMLSchema#string